Search

HCV-086

HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

GT 389-255

MAD) Phase I trials. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

rhIGFBP-3

It is developed by Insmed and is currently under phase I of the clinical trial. … rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models

Davamotecan pegadexamer

EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

GPI-0100

GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

Resatorvid

Resatorvid is an investigational compound designed for the treatment of severe sepsis.

PRTX-100

PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases

EGEN-001

EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

EVT-101

SYN-101

SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.